Does RedHill Biopharma Ltd. (RDHL) offer a good opportunity for investors?

RedHill Biopharma Ltd. (NASDAQ: RDHL) stock fell -4.59% on Monday to $0.81 against a previous-day closing price of $0.85. With 10.05 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.22 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.0200 whereas the lowest price it dropped to was $0.7800. The 52-week range on RDHL shows that it touched its highest point at $38.40 and its lowest point at $0.79 during that stretch. Beta for the stock currently stands at 2.00.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was down-trending over the past week, with a drop of -3.40%, but this was down by -12.80% over a month. Three-month performance dropped to -59.25% while six-month performance fell -85.12%. The stock lost -97.45% in the past year, while it has lost -85.55% so far this year.

Float and Shares Shorts:

At present, 5.85 million RDHL shares are outstanding with a float of 2.93 million shares on hand for trading. On Aug 30, 2023, short shares totaled 7700.0, which was 0.13% higher than short shares on Jul 30, 2023. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, CEO & Director, Mr. Gilead Raday MPhil, MSc serves as its Chief Operating Officer.

Institutional Ownership:

Through their ownership of 11.11% of RDHL’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.87% of RDHL, in contrast to 0.04% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in RDHL with 4.92% of the stake, Cowen & Co. LLC holds 288,000 shares worth 288,000. A second-largest stockholder of RDHL, Citadel Securities LLC, holds 15,729 shares, controlling over 0.27% of the firm’s shares. Two Sigma Securities LLC is the third largest shareholder in RDHL, holding 13,149 shares or 0.23% stake. With a 0.02% stake in RDHL, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 1,040 shares are owned by the mutual fund manager. The Yorkville Health Care Opportuniti, which owns about 0.01% of RDHL stock, is the second-largest Mutual Fund holder. It holds 359 shares valued at 315.0. Kivun Gemisha holds 0.01% of the stake in RDHL, owning 295 shares worth 259.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, RDHL reported revenue of $18.35M and operating income of -$9.16M. The EBITDA in the recently reported quarter was -$5.58M and diluted EPS was -$8.00.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RDHL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RDHL analysts setting a high price target of $40.00 and a low target of $40.00, the average target price over the next 12 months is $40.00. Based on these targets, RDHL could surge 4838.27% to reach the target high and rise by 4838.27% to reach the target low. Reaching the average price target will result in a growth of 4838.27% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Leave a Comment

Your email address will not be published. Required fields are marked *